Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2024-07-25 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
2024年半年度财务报告
Interim / Quarterly Report Classification · 98% confidence The document is titled "2024 年半年度财务报告" which translates to "2024 Semi-Annual Financial Report." It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and changes in equity for the half-year period ending June 30, 2024. The report explicitly states it is unaudited and includes comprehensive financial data and analysis for the half-year period. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive financial data. The document is lengthy (15,000 characters) and contains the full financial report, not just an announcement or certification. Therefore, the correct classification is IR with high confidence. H1 2024
2024-07-25 Chinese
2024年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2024 半年度报告摘要' which translates to '2024 Half-Year Report Summary'. It contains detailed financial data such as revenue, net profit, earnings per share, and asset values for the half-year period. It also includes shareholder information and notes on changes in controlling shareholders, which are typical components of an interim or quarterly financial report. The document length is about 3060 characters, which is relatively short but contains substantive financial data and analysis, not just an announcement or summary pointing to another report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-07-25 Chinese
半年度非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings Classification · 95% confidence The document is a summary table detailing non-operating fund occupation and other related party fund transactions for the half-year period of 2024. It includes financial figures such as balances at the beginning and end of the period, amounts occupied or repaid, and interest amounts. The document is relatively short (1016 characters) and appears to be a specific financial disclosure related to related party transactions and fund usage rather than a full interim or annual report. It does not contain comprehensive financial statements or detailed analysis typical of an Interim/Quarterly Report (IR) or Annual Report (10-K). Instead, it is a regulatory disclosure of related party fund usage, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-07-25 Chinese
半年报监事会决议公告
Regulatory Filings Classification · 95% confidence The document is an announcement of the resolutions passed at the 22nd meeting of the 5th Supervisory Board of 特一药业集团股份有限公司. It includes the Supervisory Board's review and approval of the company's 2024 semi-annual report and a special report on the use and storage of raised funds for the same period. The document does not contain the actual semi-annual report or detailed financial statements but rather the Supervisory Board's approval and assurance of the report's compliance and accuracy. The document length is short (1054 characters), and it serves as a formal announcement of meeting resolutions rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-07-25 Chinese
关于2024年半年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the storage and usage of funds raised by the company through various financing activities, including convertible bonds and private stock placements, for the half-year period ending June 30, 2024. It references regulatory approvals from the China Securities Regulatory Commission and Shenzhen Stock Exchange guidelines, and includes detailed tables of funds raised, used, and remaining balances. The document focuses on the management and use of raised capital rather than announcing new financing or summarizing financial results. It is not an announcement of a report but the report itself, with substantive financial data and analysis related to fundraising and capital usage. Therefore, the document fits the category of a Capital/Financing Update (CAP).
2024-07-25 Chinese
2024年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2024 年半年度报告" which translates to "2024 Semi-Annual Report". It contains detailed financial data, management discussion and analysis, business overview, financial indicators, and other comprehensive information typical of an interim or quarterly report. The report covers the period from January 1, 2024 to June 30, 2024, which is a period shorter than a full fiscal year. The document is lengthy (15,000 characters) and includes actual financial statements and substantive financial data, not just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-07-25 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.